Cargando…
Freeze-Dried Mesenchymal Stem Cell-Secretome Pharmaceuticalization: Optimization of Formulation and Manufacturing Process Robustness
Producing mesenchymal stem cell (MSC)-secretome for dose escalation studies and clinical practice requires scalable and good manufacturing practice (GMP)-compliant production procedures and formulation into a standardized medicinal product. Starting from a method that combines ultrafiltration and fr...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401234/ https://www.ncbi.nlm.nih.gov/pubmed/34452088 http://dx.doi.org/10.3390/pharmaceutics13081129 |
_version_ | 1783745502971428864 |
---|---|
author | Mocchi, Michela Bari, Elia Marrubini, Giorgio Bonda, Andrea Foglio Perteghella, Sara Tartara, Fulvio Cofano, Fabio Perna, Giuseppe di Giovannelli, Lorella Mandracchia, Delia Sorlini, Marzio Garbossa, Diego Torre, Maria Luisa Segale, Lorena |
author_facet | Mocchi, Michela Bari, Elia Marrubini, Giorgio Bonda, Andrea Foglio Perteghella, Sara Tartara, Fulvio Cofano, Fabio Perna, Giuseppe di Giovannelli, Lorella Mandracchia, Delia Sorlini, Marzio Garbossa, Diego Torre, Maria Luisa Segale, Lorena |
author_sort | Mocchi, Michela |
collection | PubMed |
description | Producing mesenchymal stem cell (MSC)-secretome for dose escalation studies and clinical practice requires scalable and good manufacturing practice (GMP)-compliant production procedures and formulation into a standardized medicinal product. Starting from a method that combines ultrafiltration and freeze-drying to transform MSC-secretome into a pharmaceutical product, the lyosecretome, this work aims to: (i) optimize the lyosecretome formulation; (ii) investigate sources of variability that can affect the robustness of the manufacturing process; (iii) modify the ultrafiltration step to obtain a more standardized final product. Design of experiments and principal component analysis of the data were used to study the influence of batch production, lyophilization, mannitol (M)/sucrose (S) binary mixture, selected as cryoprotectant excipients, and the total amount of excipients on the extracellular vesicles (EV) particle size, the protein and lipid content and the in vitro anti-elastase. The different excipients ratios did not affect residual moisture or EV particle size; simultaneously, proteins and lipids were better preserved in the freeze-dried product using the maximum total concentration of excipients (1.5% w/v) with a M:S ratio of about 60% w/w. The anti-elastase activity was instead better preserved using 0.5% w/w of M as excipient. The secretome batch showed to be the primary source of variability; therefore, the manufacturing process has been modified and then validated: the final product is now concentrated to reach a specific protein (and lipid) concentration instead of cell equivalent concentration. The new standardization approach led to a final product with more reproducible quali-quantitative composition and higher biological activity. |
format | Online Article Text |
id | pubmed-8401234 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84012342021-08-29 Freeze-Dried Mesenchymal Stem Cell-Secretome Pharmaceuticalization: Optimization of Formulation and Manufacturing Process Robustness Mocchi, Michela Bari, Elia Marrubini, Giorgio Bonda, Andrea Foglio Perteghella, Sara Tartara, Fulvio Cofano, Fabio Perna, Giuseppe di Giovannelli, Lorella Mandracchia, Delia Sorlini, Marzio Garbossa, Diego Torre, Maria Luisa Segale, Lorena Pharmaceutics Article Producing mesenchymal stem cell (MSC)-secretome for dose escalation studies and clinical practice requires scalable and good manufacturing practice (GMP)-compliant production procedures and formulation into a standardized medicinal product. Starting from a method that combines ultrafiltration and freeze-drying to transform MSC-secretome into a pharmaceutical product, the lyosecretome, this work aims to: (i) optimize the lyosecretome formulation; (ii) investigate sources of variability that can affect the robustness of the manufacturing process; (iii) modify the ultrafiltration step to obtain a more standardized final product. Design of experiments and principal component analysis of the data were used to study the influence of batch production, lyophilization, mannitol (M)/sucrose (S) binary mixture, selected as cryoprotectant excipients, and the total amount of excipients on the extracellular vesicles (EV) particle size, the protein and lipid content and the in vitro anti-elastase. The different excipients ratios did not affect residual moisture or EV particle size; simultaneously, proteins and lipids were better preserved in the freeze-dried product using the maximum total concentration of excipients (1.5% w/v) with a M:S ratio of about 60% w/w. The anti-elastase activity was instead better preserved using 0.5% w/w of M as excipient. The secretome batch showed to be the primary source of variability; therefore, the manufacturing process has been modified and then validated: the final product is now concentrated to reach a specific protein (and lipid) concentration instead of cell equivalent concentration. The new standardization approach led to a final product with more reproducible quali-quantitative composition and higher biological activity. MDPI 2021-07-23 /pmc/articles/PMC8401234/ /pubmed/34452088 http://dx.doi.org/10.3390/pharmaceutics13081129 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mocchi, Michela Bari, Elia Marrubini, Giorgio Bonda, Andrea Foglio Perteghella, Sara Tartara, Fulvio Cofano, Fabio Perna, Giuseppe di Giovannelli, Lorella Mandracchia, Delia Sorlini, Marzio Garbossa, Diego Torre, Maria Luisa Segale, Lorena Freeze-Dried Mesenchymal Stem Cell-Secretome Pharmaceuticalization: Optimization of Formulation and Manufacturing Process Robustness |
title | Freeze-Dried Mesenchymal Stem Cell-Secretome Pharmaceuticalization: Optimization of Formulation and Manufacturing Process Robustness |
title_full | Freeze-Dried Mesenchymal Stem Cell-Secretome Pharmaceuticalization: Optimization of Formulation and Manufacturing Process Robustness |
title_fullStr | Freeze-Dried Mesenchymal Stem Cell-Secretome Pharmaceuticalization: Optimization of Formulation and Manufacturing Process Robustness |
title_full_unstemmed | Freeze-Dried Mesenchymal Stem Cell-Secretome Pharmaceuticalization: Optimization of Formulation and Manufacturing Process Robustness |
title_short | Freeze-Dried Mesenchymal Stem Cell-Secretome Pharmaceuticalization: Optimization of Formulation and Manufacturing Process Robustness |
title_sort | freeze-dried mesenchymal stem cell-secretome pharmaceuticalization: optimization of formulation and manufacturing process robustness |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401234/ https://www.ncbi.nlm.nih.gov/pubmed/34452088 http://dx.doi.org/10.3390/pharmaceutics13081129 |
work_keys_str_mv | AT mocchimichela freezedriedmesenchymalstemcellsecretomepharmaceuticalizationoptimizationofformulationandmanufacturingprocessrobustness AT barielia freezedriedmesenchymalstemcellsecretomepharmaceuticalizationoptimizationofformulationandmanufacturingprocessrobustness AT marrubinigiorgio freezedriedmesenchymalstemcellsecretomepharmaceuticalizationoptimizationofformulationandmanufacturingprocessrobustness AT bondaandreafoglio freezedriedmesenchymalstemcellsecretomepharmaceuticalizationoptimizationofformulationandmanufacturingprocessrobustness AT perteghellasara freezedriedmesenchymalstemcellsecretomepharmaceuticalizationoptimizationofformulationandmanufacturingprocessrobustness AT tartarafulvio freezedriedmesenchymalstemcellsecretomepharmaceuticalizationoptimizationofformulationandmanufacturingprocessrobustness AT cofanofabio freezedriedmesenchymalstemcellsecretomepharmaceuticalizationoptimizationofformulationandmanufacturingprocessrobustness AT pernagiuseppedi freezedriedmesenchymalstemcellsecretomepharmaceuticalizationoptimizationofformulationandmanufacturingprocessrobustness AT giovannellilorella freezedriedmesenchymalstemcellsecretomepharmaceuticalizationoptimizationofformulationandmanufacturingprocessrobustness AT mandracchiadelia freezedriedmesenchymalstemcellsecretomepharmaceuticalizationoptimizationofformulationandmanufacturingprocessrobustness AT sorlinimarzio freezedriedmesenchymalstemcellsecretomepharmaceuticalizationoptimizationofformulationandmanufacturingprocessrobustness AT garbossadiego freezedriedmesenchymalstemcellsecretomepharmaceuticalizationoptimizationofformulationandmanufacturingprocessrobustness AT torremarialuisa freezedriedmesenchymalstemcellsecretomepharmaceuticalizationoptimizationofformulationandmanufacturingprocessrobustness AT segalelorena freezedriedmesenchymalstemcellsecretomepharmaceuticalizationoptimizationofformulationandmanufacturingprocessrobustness |